Exact Mass: 723.4322

Exact Mass Matches: 723.4322

Found 191 metabolites which its exact mass value is equals to given mass value 723.4322, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Fasciculol E

[(2R,3R,10S,12S,13R,14S,17R)-2,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate

C39H65NO11 (723.4557)


   

Fasciculol F

[(2R,3R,10S,12S,13R,14S,17R)-3,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-2-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate

C39H65NO11 (723.4557)


Fasciculol F is found in mushrooms. Fasciculol F is a constituent of mushrooms Naematoloma fasciculare and Naematoloma sublateritum. Constituent of mushrooms Naematoloma fasciculare and Naematoloma sublateritum. Fasciculol F is found in mushrooms.

   

3-O-Sulfogalactosylceramide (d18:1/12:0)

[(2R,5S,6R)-2-{[(2S,3R,4E)-2-dodecanamido-3-hydroxyoctadec-4-en-1-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxidanesulfonic acid

C36H69NO11S (723.4591)


3-O-Sulfogalactosylceramide is an acidic, sulfated glycosphingolipid, often known as sulfatide. This lipid occurs in membranes of various cell types, but is found in particularly high concentrations in myelin where it constitutes 3-4\\% of total membrane lipids. This lipid is synthesized primarily in the oligodendrocytes in the central nervous system. Accumulation of this lipid in the lysosomes is a characteristic of metachromatic leukodystrophy, a lysosomal storage disease caused by the deficiency of arylsulfatase A. Alterations in sulfatide metabolism, trafficking, and homeostasis are present in the earliest clinically recognizable stages of Alzheimers disease.Cerebrosides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Cerebrosides have a single sugar group linked to ceramide. The most common are galactocerebrosides (containing galactose), the least common are glucocerebrosides (containing glucose). Galactocerebrosides are found predominantly in neuronal cell membranes. In contrast glucocerebrosides are not normally found in membranes. Instead, they are typically intermediates in the synthesis or degradation of more complex glycosphingolipids. Galactocerebrosides are synthesized from ceramide and UDP-galactose. Excess lysosomal accumulation of glucocerebrosides is found in Gaucher disease. Sulfatides are glycosphingolipids. There are four types of glycosphingolipids, the cerebrosides, sulfatides, globosides and gangliosides. Sulfatides are the sulfuric acid esters of galactocerebrosides. They are synthesized from galactocerebrosides and activated sulfate, 3-phosphoadenosine 5-phosphosulfate (PAPS). 3-O-Sulfogalactosylceramide is an acidic, sulfated glycosphingolipid, often known as sulfatide. This lipid occurs in membranes of various cell types, but is found in particularly high concentrations in myelin where it constitutes 3-4\\% of total membrane lipids. This lipid is synthesized primarily in the oligodendrocytes in the central nervous system. Accumulation of this lipid in the lysosomes is a characteristic of metachromatic leukodystrophy, a lysosomal storage disease caused by the deficiency of arylsulfatase A. Alterations in sulfatide metabolism, trafficking, and homeostasis are present in the earliest clinically recognizable stages of Alzheimers disease.

   

Fasciculol E

[2,12-dihydroxy-4,4,10,13,14-pentamethyl-17-(1,5,6-trihydroxy-6-methylheptan-2-yl)-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl] 3-hydroxy-6-[(2-methoxy-2-oxoethyl)amino]-5-oxohexanoate

C39H65NO11 (723.4557)


Fasciculol E is found in mushrooms. Fasciculol E is a constituent of mushroom Naematoloma fasciculare. Constituent of mushroom Naematoloma fasciculare. Fasciculol E is found in mushrooms.

   

PE(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

(2-aminoethoxy)[(2R)-2-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z)), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

(2-aminoethoxy)[(2R)-2-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z)), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

(2-aminoethoxy)[(2R)-2-{[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(5Z,8Z,11Z,14Z,16E,18S)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z)), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

(2-aminoethoxy)[(2R)-2-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z)), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

(2-aminoethoxy)[(2R)-2-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z)), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

(2-aminoethoxy)[(2R)-2-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

(2-aminoethoxy)[(2R)-3-{[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphinic acid

C39H66NO9P (723.4475)


PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z)), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

DG(14:0/LTE4/0:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2S)-1-hydroxy-3-(tetradecanoyloxy)propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(14:0/LTE4/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(14:0/LTE4/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

   

DG(LTE4/14:0/0:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2S)-3-hydroxy-2-(tetradecanoyloxy)propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(LTE4/14:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(LTE4/14:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

   

DG(14:0/0:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-2-hydroxy-3-(tetradecanoyloxy)propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(14:0/0:0/LTE4) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

   

DG(LTE4/0:0/14:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2S)-2-hydroxy-3-(tetradecanoyloxy)propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(LTE4/0:0/14:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

   

DG(i-14:0/LTE4/0:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2S)-1-hydroxy-3-[(12-methyltridecanoyl)oxy]propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(i-14:0/LTE4/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-14:0/LTE4/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

   

DG(LTE4/i-14:0/0:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2S)-3-hydroxy-2-[(12-methyltridecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(LTE4/i-14:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(LTE4/i-14:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

   

DG(i-14:0/0:0/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-2-hydroxy-3-[(12-methyltridecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(i-14:0/0:0/LTE4) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

   

DG(LTE4/0:0/i-14:0)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2S)-2-hydroxy-3-[(12-methyltridecanoyl)oxy]propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C40H69NO8S (723.4744)


DG(LTE4/0:0/i-14:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

   

Didesacetylprotoveratrin

Didesacetylprotoveratrin

C38H61NO12 (723.4194)


   

PHDdiA-PS

1-hexadecanoyl-2-(9-hydroxy-11-carboxy-10E-undecenoyl)-sn-glycero-3-phosphoserine

C34H62NO13P (723.3959)


   

PE(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

PE(14:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C39H66NO9P (723.4475)


   

PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

PE(20:4(6E,8Z,11Z,14Z)+=O(5)/14:1(9Z))

C39H66NO9P (723.4475)


   

PE(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

PE(14:1(9Z)/20:4(5Z,8Z,11Z,13E)+=O(15))

C39H66NO9P (723.4475)


   

PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

PE(20:4(5Z,8Z,11Z,13E)+=O(15)/14:1(9Z))

C39H66NO9P (723.4475)


   

PE(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

PE(14:1(9Z)/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C39H66NO9P (723.4475)


   

PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

PE(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/14:1(9Z))

C39H66NO9P (723.4475)


   

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C39H66NO9P (723.4475)


   

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/14:1(9Z))

C39H66NO9P (723.4475)


   

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

PE(14:1(9Z)/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C39H66NO9P (723.4475)


   

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

PE(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/14:1(9Z))

C39H66NO9P (723.4475)


   

PE(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

PE(14:1(9Z)/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C39H66NO9P (723.4475)


   

PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

PE(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/14:1(9Z))

C39H66NO9P (723.4475)


   

DG(14:0/LTE4/0:0)

DG(14:0/LTE4/0:0)

C40H69NO8S (723.4744)


   

DG(LTE4/14:0/0:0)

DG(LTE4/14:0/0:0)

C40H69NO8S (723.4744)


   

DG(14:0/0:0/LTE4)

DG(14:0/0:0/LTE4)

C40H69NO8S (723.4744)


   

DG(LTE4/0:0/14:0)

DG(LTE4/0:0/14:0)

C40H69NO8S (723.4744)


   

DG(i-14:0/LTE4/0:0)

DG(i-14:0/LTE4/0:0)

C40H69NO8S (723.4744)


   

DG(LTE4/i-14:0/0:0)

DG(LTE4/i-14:0/0:0)

C40H69NO8S (723.4744)


   

DG(i-14:0/0:0/LTE4)

DG(i-14:0/0:0/LTE4)

C40H69NO8S (723.4744)


   

DG(LTE4/0:0/i-14:0)

DG(LTE4/0:0/i-14:0)

C40H69NO8S (723.4744)


   

[(2R,3R,10S,12S,13R,14S,17R)-3,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(2R,5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-2-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate

[(2R,3R,10S,12S,13R,14S,17R)-3,12-dihydroxy-4,4,10,13,14-pentamethyl-17-[(2R,5R)-1,5,6-trihydroxy-6-methylheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-2-yl] 3-hydroxy-5-[(2-methoxy-2-oxoethyl)amino]-3-methyl-5-oxopentanoate

C39H65NO11 (723.4557)


   
   
   
   
   
   
   

SHexCer 16:2;2O/13:0;O

SHexCer 16:2;2O/13:0;O

C35H65NO12S (723.4227)


   

SHexCer 15:2;2O/14:0;O

SHexCer 15:2;2O/14:0;O

C35H65NO12S (723.4227)


   

SHexCer 15:1;2O/14:1;O

SHexCer 15:1;2O/14:1;O

C35H65NO12S (723.4227)


   

SHexCer 12:2;2O/17:0;O

SHexCer 12:2;2O/17:0;O

C35H65NO12S (723.4227)


   

SHexCer 14:1;2O/15:1;O

SHexCer 14:1;2O/15:1;O

C35H65NO12S (723.4227)


   

SHexCer 17:1;2O/12:1;O

SHexCer 17:1;2O/12:1;O

C35H65NO12S (723.4227)


   

SHexCer 16:1;2O/13:1;O

SHexCer 16:1;2O/13:1;O

C35H65NO12S (723.4227)


   

SHexCer 10:1;2O/19:1;O

SHexCer 10:1;2O/19:1;O

C35H65NO12S (723.4227)


   

SHexCer 13:1;2O/16:1;O

SHexCer 13:1;2O/16:1;O

C35H65NO12S (723.4227)


   

SHexCer 11:1;2O/18:1;O

SHexCer 11:1;2O/18:1;O

C35H65NO12S (723.4227)


   

SHexCer 13:2;2O/16:0;O

SHexCer 13:2;2O/16:0;O

C35H65NO12S (723.4227)


   

SHexCer 13:0;2O/16:2;O

SHexCer 13:0;2O/16:2;O

C35H65NO12S (723.4227)


   

SHexCer 17:2;2O/12:0;O

SHexCer 17:2;2O/12:0;O

C35H65NO12S (723.4227)


   

SHexCer 14:2;2O/15:0;O

SHexCer 14:2;2O/15:0;O

C35H65NO12S (723.4227)


   

SHexCer 11:0;2O/18:2;O

SHexCer 11:0;2O/18:2;O

C35H65NO12S (723.4227)


   

Lnaps 10:0/N-22:6

Lnaps 10:0/N-22:6

C38H62NO10P (723.4111)


   

Lnaps 16:3/N-16:3

Lnaps 16:3/N-16:3

C38H62NO10P (723.4111)


   

Lnaps 22:6/N-10:0

Lnaps 22:6/N-10:0

C38H62NO10P (723.4111)


   

PI-Cer 17:1;2O/12:1;O

PI-Cer 17:1;2O/12:1;O

C35H66NO12P (723.4322)


   

PI-Cer 14:2;2O/15:0;O

PI-Cer 14:2;2O/15:0;O

C35H66NO12P (723.4322)


   

PI-Cer 13:2;2O/16:0;O

PI-Cer 13:2;2O/16:0;O

C35H66NO12P (723.4322)


   

PI-Cer 12:2;2O/17:0;O

PI-Cer 12:2;2O/17:0;O

C35H66NO12P (723.4322)


   

PI-Cer 15:1;2O/14:1;O

PI-Cer 15:1;2O/14:1;O

C35H66NO12P (723.4322)


   

PI-Cer 17:2;2O/12:0;O

PI-Cer 17:2;2O/12:0;O

C35H66NO12P (723.4322)


   

PI-Cer 13:0;2O/16:2;O

PI-Cer 13:0;2O/16:2;O

C35H66NO12P (723.4322)


   

PI-Cer 15:2;2O/14:0;O

PI-Cer 15:2;2O/14:0;O

C35H66NO12P (723.4322)


   

PI-Cer 16:2;2O/13:0;O

PI-Cer 16:2;2O/13:0;O

C35H66NO12P (723.4322)


   

PI-Cer 14:1;2O/15:1;O

PI-Cer 14:1;2O/15:1;O

C35H66NO12P (723.4322)


   

PI-Cer 16:1;2O/13:1;O

PI-Cer 16:1;2O/13:1;O

C35H66NO12P (723.4322)


   

PI-Cer 13:1;2O/16:1;O

PI-Cer 13:1;2O/16:1;O

C35H66NO12P (723.4322)


   

2-amino-3-[[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[hydroxy-[3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[hydroxy-[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propoxy]phosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-undecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-undecoxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid

C39H66NO9P (723.4475)


   
   

SHexCer 16:1;2O/14:0

SHexCer 16:1;2O/14:0

C36H69NO11S (723.4591)


   

SHexCer 15:0;2O/15:1

SHexCer 15:0;2O/15:1

C36H69NO11S (723.4591)


   

SHexCer 18:1;2O/12:0

SHexCer 18:1;2O/12:0

C36H69NO11S (723.4591)


   

SHexCer 15:1;2O/15:0

SHexCer 15:1;2O/15:0

C36H69NO11S (723.4591)


   

SHexCer 17:1;2O/13:0

SHexCer 17:1;2O/13:0

C36H69NO11S (723.4591)


   

SHexCer 16:0;2O/14:1

SHexCer 16:0;2O/14:1

C36H69NO11S (723.4591)


   

SHexCer 17:0;2O/13:1

SHexCer 17:0;2O/13:1

C36H69NO11S (723.4591)


   

SHexCer 14:1;2O/16:0

SHexCer 14:1;2O/16:0

C36H69NO11S (723.4591)


   

SHexCer 18:0;2O/12:1

SHexCer 18:0;2O/12:1

C36H69NO11S (723.4591)


   

2-amino-3-[[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

2-amino-3-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

2-amino-3-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

2-amino-3-[2,3-bis[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy]propoxy-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[2,3-bis[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy]propoxy-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

2-amino-3-[[3-decanoyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

2-amino-3-[[3-decanoyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosan-2-yl]propanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosan-2-yl]propanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradecan-2-yl]decanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradecan-2-yl]decanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]pentadecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]pentadecanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadecan-2-yl]octanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadecan-2-yl]octanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctan-2-yl]hexadecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctan-2-yl]hexadecanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodecan-2-yl]dodecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodecan-2-yl]dodecanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydecan-2-yl]tetradecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydecan-2-yl]tetradecanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadecan-2-yl]heptanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadecan-2-yl]heptanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadecan-2-yl]nonanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadecan-2-yl]nonanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyicosan-2-yl]butanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyicosan-2-yl]butanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadecan-2-yl]pentanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadecan-2-yl]pentanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydocosan-2-yl]acetamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydocosan-2-yl]acetamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridecan-2-yl]undecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridecan-2-yl]undecanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadecan-2-yl]hexanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadecan-2-yl]hexanamide

C36H69NO13 (723.4769)


   

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundecan-2-yl]tridecanamide

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundecan-2-yl]tridecanamide

C36H69NO13 (723.4769)


   

(2S)-2-amino-3-[[(2S)-3-decanoyloxy-2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[(2S)-3-decanoyloxy-2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

(2S)-2-amino-3-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

(2R)-2-amino-3-[[(2S)-2-decanoyloxy-3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2R)-2-amino-3-[[(2S)-2-decanoyloxy-3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

(2S)-2-amino-3-[2,3-bis[[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy]propoxy-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[2,3-bis[[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy]propoxy-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

(2S)-2-amino-3-[[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   

(2S)-2-amino-3-[[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

(2S)-2-amino-3-[[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C38H62NO10P (723.4111)


   
   

DGTS 33:9;O

DGTS 33:9;O

C43H65NO8 (723.471)


   
   

PC P-18:1/13:5;O2

PC P-18:1/13:5;O2

C39H66NO9P (723.4475)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Hex2Cer 14:0;O2/10:0

Hex2Cer 14:0;O2/10:0

C36H69NO13 (723.4769)


   

Hex2Cer 24:0;O2

Hex2Cer 24:0;O2

C36H69NO13 (723.4769)


   

LacCer 14:0;O2/10:0

LacCer 14:0;O2/10:0

C36H69NO13 (723.4769)


   
   
   
   

IPC 12:2;O2/17:0;O

IPC 12:2;O2/17:0;O

C35H66NO12P (723.4322)


   
   
   

IPC 14:2;O2/15:0;O

IPC 14:2;O2/15:0;O

C35H66NO12P (723.4322)


   
   
   

IPC 15:2;O2/14:0;O

IPC 15:2;O2/14:0;O

C35H66NO12P (723.4322)


   
   
   

IPC 16:2;O2/13:0;O

IPC 16:2;O2/13:0;O

C35H66NO12P (723.4322)


   
   

IPC 17:2;O2/12:0;O

IPC 17:2;O2/12:0;O

C35H66NO12P (723.4322)


   
   

IPC 18:2;O2/11:0;O

IPC 18:2;O2/11:0;O

C35H66NO12P (723.4322)


   
   

IPC 19:2;O2/10:0;O

IPC 19:2;O2/10:0;O

C35H66NO12P (723.4322)


   
   
   
   

ST 29:4;O8;HexNAc

ST 29:4;O8;HexNAc

C37H57NO13 (723.383)


   

5-{[(1r,3as,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[(1r,3as,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

5-{[(1r,3as,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[(1r,3as,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

(3r)-5-{[(1r,3as,5ar,7r,8r,9ar,11s,11as)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

(3r)-5-{[(1r,3as,5ar,7r,8r,9ar,11s,11as)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

(1r,2s,6r,9r,10s,11r,12r,13s,14s,15r,16s,17r,18r,19s,22s,23s,25r)-10,12,14,16,17,23-hexahydroxy-22-{[(3s)-3-hydroxy-3-methyl-2-oxopentyl]oxy}-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl (2r)-2-methylbutanoate

(1r,2s,6r,9r,10s,11r,12r,13s,14s,15r,16s,17r,18r,19s,22s,23s,25r)-10,12,14,16,17,23-hexahydroxy-22-{[(3s)-3-hydroxy-3-methyl-2-oxopentyl]oxy}-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl (2r)-2-methylbutanoate

C38H61NO12 (723.4194)


   

5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

5-{[7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-(1,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-(1,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

5-{[8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-(1,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

5-{[8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-(1,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

(3s,6r,9s,12s,15r)-3-[(2s)-butan-2-yl]-5,8,11,14,17-pentahydroxy-9-[(1r)-1-hydroxyethyl]-12-(hydroxymethyl)-6,15-bis(2-methylpropyl)-19-[(2z)-non-2-en-1-yl]-1-oxa-4,7,10,13,16-pentaazacyclononadeca-4,7,10,13,16-pentaen-2-one

(3s,6r,9s,12s,15r)-3-[(2s)-butan-2-yl]-5,8,11,14,17-pentahydroxy-9-[(1r)-1-hydroxyethyl]-12-(hydroxymethyl)-6,15-bis(2-methylpropyl)-19-[(2z)-non-2-en-1-yl]-1-oxa-4,7,10,13,16-pentaazacyclononadeca-4,7,10,13,16-pentaen-2-one

C37H65N5O9 (723.4782)


   

(3r)-5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

(3r)-5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)


   

10,12,14,16,17,23-hexahydroxy-22-[(3-hydroxy-3-methyl-2-oxopentyl)oxy]-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl 2-methylbutanoate

10,12,14,16,17,23-hexahydroxy-22-[(3-hydroxy-3-methyl-2-oxopentyl)oxy]-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl 2-methylbutanoate

C38H61NO12 (723.4194)


   

(3r)-5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

(3r)-5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-8,11-dihydroxy-3a,6,6,9a,11a-pentamethyl-1-[(2r,5r)-1,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-n-(2-methoxy-2-oxoethyl)-3-methyl-5-oxopentanimidic acid

C39H65NO11 (723.4557)